Showing 26–50 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Nunn AJ, Phillips PPJ, Meredith SK, Chiang CY, Conradie F, et al.
…idrug-resistant tuberculosis who received existing drugs in regimens shorter than that recommended by the World Health Organization (WHO) in 2011. Methods We conducted a phase 3 noninferiority trial in participants with rifampin-resistant tuberculosis that was susceptible to fluo…
Taipei Medical University WanFang Hospital
… (Ri-TB) and TB patients for whom rifamycin-sparing anti-TB regimens are preferred due to drug-drug interaction (Rs-TB). Trial intervention The novel regimen will be given in two phases: 1. An intensive phase consisting of isoniazid, bedaquiline, moxifloxacin and pyrazinamide …
Marcela Muñoz-Torrico, Rafael Laniado-Laborín, Jorge Rojas-Serrano, Eduardo Becerril-Vargas, Wendy Cinecio-Chávez, et al.
…ere mainly related to linezolid use. **CONCLUSIONS:** Oral regimens appear to be effective, although toxicity to linezolid requires strict patient monitoring.
Goodall RL, Meredith SK, Nunn AJ, Bayissa A, Bhatnagar AK, et al.
…EAM stage 2, we aimed to compare two bedaquiline-containing regimens with the 9-month STREAM stage 1 regimen. Methods We did a randomised, phase 3, non-inferiority trial in 13 hospital clinics in seven countries, in individuals aged 15 years or older with rifampicin-resistant tub…
Wenhong Zhang, PhD
The purpose of this study is to assess the efficacy, safety and tolerability of a combination of levofloxacin, linezolid, cycloserine and pyrazinamide (or clofazimine if resistant to pyrazinamide) treatments for 24 to 32 weeks (regimen consisted of clofazimine for 36\~44 weeks) i…
Raehan Satya Deanasa, Arya Marganda Simanjuntak, Fara Syafira, Putri Mahirah Afladhanti, Anisa Hawari, et al.
… and moxifloxacin was active in ABSTRACT INTRODUCTION Newer regimens are needed and expected to have a shorter therapeutic time to increase drug adherence to completion in drug sensitive tuberculosis (DS-TB) patients.METHODS We conducted first a systematic review and meta-analysi…
Suman Saurabh, Pankaj Bhardwaj
…ed as a key drug with its inclusion in all the standardized regimens for drug-resistant tuberculosis. Therefore, it is important to prevent the emergence of resistance to bedaquiline. Active drug safety monitoring (aDSM) should be rigorously implemented in addition to ensuring co…
Khan PY, Franke MF, Hewison C, Seung KJ, Huerga H, et al.
…le agents, in use for decades, and endorsed all-oral longer regimens. However, questions remain about the role of the injectable agent, particularly in the context of regimens using new and repurposed drugs. We compared the effectiveness of an injectable-containing regimen to tha…
Ryckman TS, Schumacher SG, Lienhardt C, Sweeney S, Dowdy DW, et al.
…tent to which future improvements in tuberculosis treatment regimens could offset potential increases in drug costs. Methods In this modelling analysis, we used an ingredients-based approach to estimate prices at which novel regimens for rifampin-susceptible and rifampin-resistan…
Vijay Kumar, G S Sri Bharathi, Mohit Bhatia, Sankha Shubhra Chakrabarti, Upinder Kaur, et al.
…nalyze therapeutic outcomes with bedaquiline-based all-oral regimens for drug-resistant tuberculosis. A prospective observational study was conducted from August 2022 to March 2024 and patients of drug-resistant tuberculosis on all-oral regimens were enrolled. Among 100 patients …
Gupta A, Juneja S, Babawale V, Rustam Majidovich N, Ndjeka N, et al.
…e rollout of new WHO-recommended shorter all-oral treatment regimens for drug-resistant TB (DR-TB), which remains a public-health crisis. The all-oral, 6-month BPaL/M regimen comprises 3-4 drugs: pretomanid used in combination with bedaquiline and linezolid, with or without moxif…
Norbert Ndjeka, Rubeshan Perumal, Kamila Romanowski, Hlengani Mathema, Lateef Babatunde Amusa, et al.
**BACKGROUND:** Shorter all-oral regimens for the treatment of multidrug-resistant tuberculosis or rifampicin-resistant tuberculosis (MDR/RR-TB) have improved efficacy, but their performance under programmatic conditions remains insufficiently characterized. **METHODS:** We retr…
Kohler S, Sitali N, Achar J, Paul N
…nd their import are costly. We assessed how shorter TB drug regimens, which were non-inferior or superior in recent TB trials, can affect the costs for purchasing and importing TB drugs. Methods We estimated the drug costs and import costs of 39 longer and shorter TB drug regimen…
Adriana Chacón, Yamile Celis Bustos, Dany Martinez, Felix Chong, Clara Freile, et al.
…ogrammatic cohort, the nine-month all-oral shorter and BPaL regimens were associated with favorable treatment outcomes, acceptable safety profiles, improved adherence, and reduced loss to follow-up compared with injectable-based therapy. These findings supported Ecuador’s …
Malaisamy Muniyandi, Balaji Ramraj, Sathishkumar Vadamalai, Sahil Abdul Salam, Bella Devaleenal, et al.
**BACKGROUND:** Short-course regimens are currently explored to improve multidrug-resistant tuberculosis effects, reduce costs, as well as enhance patient adherence. Currently, we are determining the most cost-effective shorter regimen out of seven short-course regimens (6-9 …
Xueyi Chen, Oscar J Nino-Meza, Mona O. Sarhan, Bhavatharini Arun, Byeonghoon Jeon, et al.
…dicted tissue exposures which were used to design optimized regimens (Fig.1).Figure 1.Study design. Dynamic positron emission tomography (PET) was performed using radioanalogs of antibiotics (18F-pretomanid, 18F-sutezolid, 18F-linezolid and 76Br-bedaquiline) active against MDR st…
Yilin Zhang, Yang Li, Yuanyuan Chen, Cui Cai, Hengzhong Yi, et al.
…IVES:** Effective rifampicin-resistant tuberculosis (RR-TB) regimens often include multiple QT-prolonging drugs, necessitating evaluation across different combinations. **METHODS:** Using pooled electrocardiogram data from two trials, three QT-prolonging shorter regimens for RR-…
Ionescu AM, Mpobela Agnarson A, Kambili C, Metz L, Kfoury J, et al.
…ared the cost-effectiveness of bedaquiline (BDQ) containing regimens with injectable containing regimens (short-course regimen [SCR] and long-course regiman [LCR]) in India, Russia, and South Africa. Methods The analysis evaluated the direct costs of DR-TB treatment which include…
Yilin Zhang, Yang Li, Yan Ren, Ting Li, Yajiao Xing, et al.
…great threat to global health. Increasing evidence of novel regimens in trial settings has risen, but the combinations of oral shorter regimens have not been optimised. An evaluation of the efficacy and safety of short-term regimens utilizing various drug combinations is essentia…
Hasan T, Medcalf E, Nyang'wa BT, Egizi E, Berry C, et al.
…cal considerations in shifting to shorter tuberculosis (TB) regimens. Novel 6-month oral regimens that include bedaquiline (B), pretomanid (Pa), and linezolid (L), with or without a fourth drug, have been shown to be as or more effective than the established longer regimens for t…
Heping Xiao, M.D
Multi-center, prospective study is performed to investigate the efficacy of new short-course regimen for retreatment pulmonary tuberculosis patients. To obtain optimized short-course regimen, decrease treatment cost and improve success rate. China is the country with the second…
Zarir Udwadia, Jennifer Furin
…n it comes to rolling out bedaquiline (BDQ)-based, all-oral regimens for drug-resistant forms of tuberculosis (DR-TB). India is home to the largest population of people living with DR-TB in the world,[2] and improving access to innovative diagnostic and therapeutic approaches is …
Sweeney S, Laurence YV, Berry C, Singh MP, Dodd M, et al.
…und New 6-month rifampicin-resistant tuberculosis treatment regimens containing bedaquiline, pretomanid, and linezolid (BPaL) with or without moxifloxacin or clofazimine, could improve treatment efficacy, safety, and tolerability, and free up resources within the health system. F…
Lienhardt C, Dooley KE, Nahid P, Wells C, Ryckman TS, et al.
…evelopers aware of both the important features of treatment regimens, and patient and programmatic needs at the country level. In view of recent ground-breaking advances in tuberculosis treatment, WHO has revised and updated these regimen profiles. We used a similar process as fo…
Е. А. Бородулина, М.В. Ураксина, E. P. Еremenko, T. M. Larionova, A. N. Gerasimov
…tment method seems relevant. Aim: To analyze the prescribed regimens and the reason for their correction in newly identified patients before verifying the diagnosis of tuberculosis. Material and Methods. The following methods were used to detect MBT: luminescent microscopy, molec…